It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Central nervous system ischemic injury features neuronal dysfunction, inflammation and breakdown of vascular integrity. Here we show that activation of endothelial caspase-9 after hypoxia-ischemia is a critical event in subsequent dysfunction of the blood-retina barrier, using a panel of interrelated ophthalmic in vivo imaging measures in a mouse model of retinal vein occlusion (RVO). Rapid nonapoptotic activation of caspase-9 and its downstream effector caspase-7 in endothelial cells promotes capillary ischemia and retinal neurodegeneration. Topical eye-drop delivery of a highly selective caspase-9 inhibitor provides morphological and functional retinal protection. Inducible endothelial-specific caspase-9 deletion phenocopies this protection, with attenuated retinal edema, reduced inflammation and preserved neuroretinal morphology and function following RVO. These results reveal a non-apoptotic function of endothelial caspase-9 which regulates blood-retina barrier integrity and neuronal survival, and identify caspase-9 as a therapeutic target in neurovascular disease.
Retinal vein occlusion can cause blindness, and features neuronal dysfunction, inflammation and breakdown of vascular integrity. Here the authors report a non-apoptotic role of endothelial caspase-9 in regulating blood-retina barrier integrity and neuronal survival, which can be therapeutically targeted in a mouse model of retinal vein occlusion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Columbia University, Department of Pathology & Cell Biology; Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
2 Columbia University, Department of Pharmacology; Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)
3 Sanford Burnham Prebys Medical Discovery Institute La Jolla, NCI-designated Cancer Center, La Jolla, USA (GRID:grid.479509.6) (ISNI:0000 0001 0163 8573)
4 Columbia University, Department of Pathology & Cell Biology; Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University, Department of Neurology; Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729); Columbia University, The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain; Vagelos College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729)